Posted on

Ketamine One Adds Seattle Location To US Clinical Network

Ketamine One Adds Seattle Location To US Clinical Network

The Clinic is in Association with Dr. Tami Meraglia, National Best-Selling  Author and Frequent Media Guest  

Vancouver, British Columbia, December 8, 2021 / Globe Newswire / – KetamineOne Capital  Limited (“Ketamine One” or the “Company”) (NEO: MEDI) (OTC: KONEF) (FRA: MY0),  a company focused on consolidating medical clinics and becoming a North American leader in  mental health treatments, is pleased to announce that it has been engaged by Dr. Tami Meraglia to  establish a ketamine infusion clinic in Seattle, Washington. The new clinic will operate as Seattle  Ketamine Infusions (“SKI” or the “Clinic”) and be located at 311 West Republican Street. Dr.  Meraglia is focused on the areas of personalized intravenous (“IV”) treatments and is also a  national best-selling author and frequent media guest regarding total health and wellness topics.  Ketamine One will provide training, protocol development, and ongoing support for the Clinic,  with the first patient treatments expected at SKI in early 2022.  

Management Commentary  

“Helping Dr. Tami set up and open a ketamine clinic in the Seattle market is an exciting project  for Ketamine One. We are looking forward to sharing our expertise and support, while also gaining  from Dr. Tami’s ability to engage with a large national audience,” said Adam Deffett, Interim CEO  of Ketamine One. “Ketamine One continues to move closer to achieving its goal of becoming a  leader in the mental health space across North America. By establishing great relationships with  medical experts in new markets, such as Seattle, our ability to transfer knowledge is increasing  and that is all for the benefit of patients,” added Mr. Deffett.  

ABOUT KETAMINE ONE 

KetamineOne Capital Limited (formerly Myconic Capital Corp.) is a company focused on  consolidating medical clinics and becoming a North American leader in mental health treatments.  It is working to provide the critical infrastructure needed to develop and deliver breakthrough  mental health treatments. Currently, Ketamine One has a network of clinics across North America, 

with plans to further consolidate the highly fragmented industry. KGK Science Inc. is the  Company’s wholly owned contract research division, which places it at the forefront of premium  clinical research based on the subsidiary’s history and extensive experience in pharmaceuticals,  cannabis, and the emerging psychedelic medicine industries. As a collective enterprise, Ketamine  One is dedicated to helping solve the growing need for safe and accessible mental health therapy.  

On behalf of:  

KETAMINE ONE 

“Adam Deffett”  

Adam Deffett, Interim CEO  

For further information, please contact:  

Nick Kuzyk, Investor Relations  

Tel: 1-844-PHONE-K1 (1-844-746-6351)  

Email: IR@ketamine.one  

Web: www.ketamine.one 

Twitter: @KetamineOne  

Notice Regarding Forward-Looking Information: 

This news release contains forward-looking statements including but not limited to statements regarding the Company’s business, assets or investments, as well as other statements that are not historical facts. Readers are cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks and uncertainties, both general and specific, that contribute to the possibility that the predictions, forecasts, projections and other forward-looking statements will not occur, which may cause actual performance and results in future periods to differ materially from any estimates or projections of future performance or results expressed or implied by such forward looking statements. These assumptions, risks and uncertainties include, among other things, the state of the economy in general and capital markets in particular, investor interest in the business and prospects of the Company.  

The forward-looking statements contained in this news release are made as of the date of this news release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities law. Additionally, the Company undertakes no obligation to comment on the expectations of, or statements made, by third parties in respect of the matters discussed above.  

INTERESTED IN WORKING WITH KETAMINE ONE?

If you’re interested in being a financial partner, clinic partner, or community advocate, we’d love to talk. partners@ketamine.one

Posted on

Ketamine One Partners with Cognetivity Neurosciences in Collaborative Clinical Study on Depression and PTSD

Ketamine One Partners with Cognetivity Neurosciences in Collaborative Clinical Study on Depression and PTSD

VANCOUVER, British Columbia, Dec. 02, 2021 (GLOBE NEWSWIRE) — KetamineOne Capital Limited (“Ketamine One” or the “Company”) (NEO: MEDI) (OTC: KONEF) (FRA: 6FC), a company focused on consolidating medical clinics and becoming a North American leader in mental health treatments, is pleased to announce that it is entering into a collaborative partnership with Cognetivity Neurosciences Ltd. (CSE: CGN; OTCQB: CGNSF; FWB: 1UB) (“Cognetivity”) to study and develop assessments for depression and post-traumatic stress disorder (“PTSD”).

In the initial stage of the partnership, Cognetivity and Ketamine One will partner on two separate clinical studies, one for depression and the second for PTSD. Protocols for both studies have received Institutional Review Board (“IRB”) approval and patient recruitment is expected to occur in early 2022. Ketamine One’s wholly owned subsidiary, KGK Science Inc., will lead the study, while Cognetivity will lead the analysis.

Ketamine One is a next-generation health and wellness company focused on transforming the treatment of mental health by providing ketamine-assisted therapy and psychedelic medicines. Based in Canada and operating clinics throughout North America, the firm is dedicated to building the critical infrastructure needed to provide potentially breakthrough and life-changing treatments for conditions such as anxiety, PTSD, chronic pain and addiction.

Cognetivity’s Integrated Cognitive Assessment (“ICA”) technology has already been deployed throughout Ketamine One’s network of clinics in North America after the two companies entered into a commercial agreement earlier this year. In the latest phase of their collaboration, the ICA will be used to monitor changes in patients’ cognitive ability as they undergo ketamine-assisted treatment for depression and PTSD.

The clinical studies will add to the extensive body of data validating the ICA’s use as a cognitive testing tool. It has already been widely deployed in clinical care, from North America and the Middle East to clinics in the UK’s National Health Service. The project will also generate novel intellectual property regarding the ICA’s predictive and long-term monitoring capabilities – not only on a stand-alone basis, but in combination with additional variables, including data from wearable devices, to support the creation of dedicated new products for specialist care in the areas of depression and PTSD.

It is well documented that there is vast potential for improvement in the treatment of such conditions. According to the World Health Organization, mental health disorders account for 28% of the global burden of disability-adjusted life years among non-communicable diseases – more than cardiovascular disease or cancer. Every year, more than 12 billion working days are lost due to mental health conditions, costing the global economy USD 16 trillion in economic output between 2011 and 2030. The global market for PTSD therapeutics is expected to reach USD 3.1 billion by 20271, with the global market for the treatment of anxiety disorders and depression predicted to exceed 13 billion by the same year2.

Management Commentary

“We’re delighted to be extending our relationship with Cognetivity through this exciting new research project,” said Adam Deffett, Interim CEO of Ketamine One. “Depression and PTSD are sadly very common conditions and existing approaches to treating them leave a lot to be desired. With the crucial involvement of the ICA, this study will further demonstrate the power of our therapies as we pursue our goal of changing how mental health is treated across North America.”

Also commenting on the announcement, Dr. Sina Habibi, CEO of Cognetivity, said, “It’s great to be working with Ketamine One on these clinical studies. We are very excited about obtaining high-quality clinical validation data on the use of the ICA to assess and monitor patients with depression and PTSD, and developing exciting new technology to better serve this huge market. These disease areas represent important use cases for the ICA beyond its core application as a device for dementia detection and diagnosis, and the fact that it can transition so smoothly into this new space confirms the strength of its fundamental capabilities and the ongoing global need for much-improved cognitive testing across a huge number of areas.”

ABOUT COGNETIVITY NEUROSCIENCES LTD.

Cognetivity is a technology company that has created a cognitive testing platform for use in medical, commercial and consumer environments. Cognetivity’s ICA uses Artificial Intelligence and machine learning techniques to help detect the earliest signs of cognitive impairment by testing the performance of large areas of the brain. The ICA is currently available for clinical use in the USA, UK and Europe, with regulatory approval for other regions planned for 2022.

For more information, please visit: www.cognetivity.com or contact: info@cognetivity.com.

ABOUT KETAMINE ONE

KetamineOne Capital Limited (formerly Myconic Capital Corp.) is a company focused on consolidating medical clinics and becoming a North American leader in mental health treatments. It is working to provide the critical infrastructure needed to develop and deliver breakthrough mental health treatments. Currently, Ketamine One has a network of clinics across North America, with plans to further consolidate the highly fragmented industry. KGK Science Inc. is the Company’s wholly owned contract research division, which places it at the forefront of premium clinical research based on the subsidiary’s history and extensive experience in pharmaceuticals, cannabis, and the emerging psychedelic medicine industries. As a collective enterprise, Ketamine One is dedicated to helping solve the growing need for safe and accessible mental health therapy.

On behalf of:

KETAMINE ONE

“Adam Deffett“
Adam Deffett, Interim CEO

For further information, please contact:

Nick Kuzyk, Investor Relations
Tel: 1-844-PHONE-K1 (1-844-746-6351)
Email: IR@ketamine.one
Web: www.ketamine.one
Twitter: @KetamineOne

Notice Regarding Forward-Looking Information:

This news release contains forward-looking statements including but not limited to statements regarding the Company’s business, assets or investments, as well other statements that are not historical facts. Readers are cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks and uncertainties, both general and specific, that contribute to the possibility that the predictions, forecasts, projections and other forward-looking statements will not occur, which may cause actual performance and results in future periods to differ materially from any estimates or projections of future performance or results expressed or implied by such forward-looking statements. These assumptions, risks and uncertainties include, among other things, the state of the economy in general and capital markets in particular, investor interest in the business and prospects of the Company.

The forward-looking statements contained in this news release are made as of the date of this news release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities law. Additionally, the Company undertakes no obligation to comment on the expectations of, or statements made, by third parties in respect of the matters discussed above.
Endnotes

‍

INTERESTED IN WORKING WITH KETAMINE ONE?

If you’re interested in being a financial partner, clinic partner, or community advocate, we’d love to talk. partners@ketamine.one

Posted on

Ketamine One Subsidiary IRP Health Opens Two New Veteran-Focused Clinics

Ketamine One Subsidiary IRP Health Opens Two New Veteran-Focused Clinics

The Previously Announced Open Label Study of Patients with PTSD Who Are Undergoing IRP Health’s Proprietary 12-Week Physical Therapy Program Has Received Ethics Approval

VANCOUVER, British Columbia, Nov. 16, 2021 (GLOBE NEWSWIRE) — KetamineOne Capital Limited (“Ketamine One” or the “Company”) (NEO: MEDI) (OTC: KONEF) (Frankfurt: 6FC), a company focused on consolidating medical clinics and becoming a North American leader in mental health treatments, is pleased to announce that its wholly owned subsidiary, IRP Health Ltd. (“IRP” or the “Subsidiary”), recently opened its Comox Valley and Ottawa clinics (the “Two Clinics”). As previously announced, the Two Clinics are veteran-focused facilities and multidisciplinary in nature. To date, IRP has successfully performed over 10,000 unique treatments for past or present personnel of the Canadian Armed Forces and the Royal Canadian Mounted Police (“RCMP”), as well as first responders including firefighters, law enforcement officers, paramedics and emergency medical technicians.

The Comox Valley location is located at 780 30th Street in Courtenay, British Columbia, as the Comox Valley is one of the top retirement destinations in Canada for military veterans. The clinic is currently past the mid-way point of its inaugural program for RCMP personnel. The Ottawa clinic is located at #305 1385 Bank Street, in an area that has a local population of over 9,000 veterans. The clinic’s practitioners have begun providing veterans with private, mental health-focused Occupational Therapy sessions. IRP continues to work toward establishing clinic locations in Halifax and Surrey, as also previously announced.

Additionally, the previously announced open label study of patients with post-traumatic stress disorder (the “PTSD Study”) who are undergoing IRP’s proprietary, 12-week physical therapy program, in affiliation with Ketamine One’s wholly owned contract research organization KGK Science Inc (“KGK”), has recently received ethics approval. The next stage in preparation for the PTSD Study is to initiate a participant recruitment campaign and KGK expects to begin data collection early in 2022. A secondary benefit of the PTSD Study is that it will provide an opportunity for veterans who do not qualify for funding through Veterans Affairs Canada to participate in IRP’s beneficial program.

Management Commentary

“I would like to commend Steven Inglefield and his team for getting IRP’s Comox Valley and Ottawa clinics to operational status and for beginning to treat veterans and first responders in multidisciplinary ways. Ketamine One continues to be a leader in mental health in Canada, and North America, thanks to the hard work of its employees,” said Adam Deffett, Interim CEO of Ketamine One. “I am also excited about the advancement of the PTSD Study, which is a great example of two of our subsidiaries, IRP and KGK, working together with the goal of advancing the field mental health. As Canada’s only group of physical rehabilitation clinics exclusively treating members of the veteran and first responder population, IRP is filling a critical role in providing customized treatment programs for patients and is seeing strong demand for its services,” added Mr. Deffett.

ABOUT KETAMINE ONE

KetamineOne Capital Limited (formerly Myconic Capital Corp.) is a company focused on consolidating medical clinics and becoming a North American leader in mental health treatments. It is working to provide the critical infrastructure needed to develop and deliver breakthrough mental health treatments. Currently, Ketamine One has a network of clinics across North America, with plans to further consolidate the highly fragmented industry. KGK Science Inc. is the Company’s wholly-owned contract research division, which places it at the forefront of premium clinical research based on the subsidiary’s history and extensive experience in pharmaceuticals, cannabis, and the emerging psychedelic medicine industries. As a collective enterprise, Ketamine One is dedicated to helping solve the growing need for safe and accessible mental health therapy.

On behalf of:

KETAMINE ONE

“Adam Deffett”
Adam Deffett, Interim CEO

For further information, please contact:

Nick Kuzyk, Investor Relations
Tel: 1-844-PHONE-K1 (1-844-746-6351)
Email: IR@ketamine.one
Web: www.ketamine.one
Twitter: @KetamineOne

Notice Regarding Forward-Looking Information:

This news release contains forward-looking statements including but not limited to statements regarding the Company’s business, assets or investments, as well other statements that are not historical facts. Readers are cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks and uncertainties, both general and specific, that contribute to the possibility that the predictions, forecasts, projections and other forward-looking statements will not occur, which may cause actual performance and results in future periods to differ materially from any estimates or projections of future performance or results expressed or implied by such forward-looking statements. These assumptions, risks and uncertainties include, among other things, the state of the economy in general and capital markets in particular, investor interest in the business and prospects of the Company.

The forward-looking statements contained in this news release are made as of the date of this news release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities law. Additionally, the Company undertakes no obligation to comment on the expectations of, or statements made, by third parties in respect of the matters discussed above.